ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
3.430
+0.020 (0.59%)
At close: Nov 4, 2026, 4:00 PM EST
3.470
+0.040 (1.17%)
After-hours: Nov 4, 2026, 5:43 PM EST
ProMIS Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
11
Market Cap
30.76M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
PMN News
- 1 day ago - ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026 - GlobeNewsWire
- 2 days ago - ProMIS Neurosciences price target lowered to $15 from $29 at Roth Capital - TheFly
- 5 days ago - Promis Neurosciences Inc trading resumes - TheFly
- 5 days ago - Promis Neurosciences Inc trading halted, volatility trading pause - TheFly
- 4 weeks ago - ProMIS Neurosciences appoints Ivana Rubino as chief commercial officer - TheFly
- 4 weeks ago - ProMIS Neurosciences Appoints Seasoned Alzheimer's and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer - GlobeNewsWire
- 7 weeks ago - ProMIS Neurosciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 7 weeks ago - ProMIS Neurosciences Transcript: Moody Capital Disruptive Growth & Life Science Conference - Transcripts